CSF2 and neoplasm: MDSCs have also been shown to affect the potency of CAR T cells, where targeting tumor MDSCs by anti-Gr1, anti-GM-CSF, or anti-PD-L1 antibody has improved treatment efficacy of anti-CEA CAR T cells in colon cancers [156].